2nd treatment for EGFR+ NSCLC with exon 20 insertion mutations
People’s tumors got smaller* or disappeared† with RYBREVANT®
of people responded (tumors got smaller* or disappeared†) with RYBREVANT®.
- 36% had tumors get smaller*
- 4% had tumors disappear†
Of people who responded, half were still responding at 11.1 months. This result lasted for 6 months or longer for 63% of people whose tumors disappeared or got smaller.
About the clinical trial
These results are from a clinical trial where 81 people with advanced NSCLC with received RYBREVANT® alone as a second treatment when their disease got worse during or after treatment with platinum-based chemotherapy. About the people in the clinical trial:
- Over half of the people never smoked (53%)
- Most of the people were women (59%)
†Tumors getting smaller may also be called a partial response. This means the tumor got measurably smaller but is still detectable.
*Tumors disappearing may also be called a complete response. This does not necessarily mean the cancer has been cured.
EGFR+ = mutated epidermal growth factor receptor; NSCLC = non–small cell lung cancer
Side effects
There are side effects that you may experience during treatment with RYBREVANT®.
Savings & support
Once prescribed a RYBREVANT®-based treatment, connect with a Care Navigator for your support needs.
